Morgan Stanley raised the firm’s price target on Kymera Therapeutics (KYMR) to $49 from $45 and keeps an Equal Weight rating on the shares. With the recent Q3 earnings update, through which management solidified the company’s focus on I&I and reiterated key pipeline time lines, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $52 from $45 at Guggenheim
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift
- Kymera Therapeutics files automatic mixed securities shelf
- Kymera Therapeutics reports Q3 EPS (82c), consensus (84c)
Questions or Comments about the article? Write to editor@tipranks.com